NeuroMab™ Anti-OPN BBB Shuttle Antibody,Clone NR1361P

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Clone Number

NR1361P

Applications

FC; ELISA; Block; Inhib; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Neuroinflammation

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

SPP1

Official Name

SPP1

Full Name

Secreted phosphoprotein 1

Alternative Names

BNSP;
Bone sialoprotein 1;
Bone sialoprotein I;
BSP I;
BSPI;
Early T lymphocyte activation 1;
ETA 1;
ETA1;
MGC110940;
Nephropontin;
OPN;
Osteopontin;

Product Pictures

Block

Fig.2 illustrates anti-OPN antibodies, 2G2 and 2H2, blocking binding of purified αvβ3 to the osteopontin antigen, OPN20.

The data are shown as mean±SE for 8 animals, 7 animals and 5 animals in the control group, 25 mg/kg group and 50 mg/kg group, respectively. *p<0.05, **p<0.01: significantly different from control group as determined by Dunnet's multiple comparison test.

Block

Fig.3 illustrates reduction of tumor size of beige nude mice injected with IGROV-1 human ovarian cancer cells using anti-OPN antibodies, 2G2, administered at 13.5 mg/kg or 27 mg/kg.

FuncS

Fig.4 illustrates reduction of tumor size of beige nude mice injected with IGROV-1 human ovarian cancer cells using anti-OPN antibodies, 2G2, in comparison with anti-GP120 antibodies.

FuncS

Fig.5 illustrates reduction of tumor size of beige nude mice injected with IGROV-1 human ovarian cancer cells using anti-OPN antibodies, 2G2, administered at 13.5 mg/kg or 27 mg/kg.

Block

Fig.1 illustrates anti-OPN antibodies, 2G2 and 2H2, blocking attachment of MDA-MB-435 highly metastatic human breast carcinoma cells to the osteopontin antigen, OPN20.

Publications